Esperion Therapeutics Inc · Q3 2023 earnings

Briefing

Esperion's Q3 2023 financial results demonstrated strong revenue growth driven by U.S. net product revenue and collaboration revenue, accompanied by strategic progress in label expansion and cardiovascular risk reduction indications.

Esperion reported a 79% increase in total revenue to $34.0 million for Q3 2023, driven by a 45% increase in U.S. net product revenue and a 174% increase in collaboration revenue. The company also made progress toward label expansion, with FDA acceptance of cardiovascular risk reduction indication submissions in the U.S. The company reported a net loss of $41.3 million, and is preparing for new labels and sales organization changes to maximize the potential of NEXLETOL and NEXLIZET.

• Total revenue increased by 79% year-over-year to $34.0 million.
• U.S. net product revenue grew by 45% year-over-year to $20.3 million.
• Collaboration revenue increased by 174% year-over-year to $13.7 million.
• FDA accepted applications for expanded cardiovascular risk reduction indications with a PDUFA date of March 31.

Headline financials

Revenue & EPS history

The company expects full year 2023 operating expenses to be approximately $225 million to $245 million, including $25 million in non-cash expenses related to stock compensation.